A new priority review was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) on January 12, 2025, entitled “Mikhail ‘Misha’ Blagosklonny’s enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.”
Aging Journal
Dennis Mangan and Dr. Mikhail Blagosklonny discuss how Dr. Blagosklonny’s cancer research led him to the study of aging, whether rapamycin is the most important anti-aging intervention currently available, his skepticism about metformin as an anti-aging drug, and more.
PRESS RELEASE: Dr. Mikhail Blagosklonny published a new review paper in Aging (Aging-US), entitled, “Hallmarks of cancer and hallmarks of aging.”